|
| Press Releases |
|
 |
|
| Saturday, August 2, 2025 |
|
|
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies |
| Everest Medicines (HKEX: 1952.HK) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash. more info >> |
|
| Friday, July 25, 2025 |
|
|
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million |
| Everest Medicines (HKEX 1952.HK, Everest or the " Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and subscription agreement with the placing agents and its controlling shareholder, CBC Group (the "Sellers"), for a top-up placement of 22,561,000 shares to raise approximately HK$1,572.50 million, representing approximately 6.87% of the total number of Shares in issue as at the date of this announcement, and approximately 6.45% of the total number of Shares in issue. more info >> |
|
| Friday, July 4, 2025 |
|
|
Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation |
| Everest Medicines (HKEX: 1952.HK) recently unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day held in Shanghai. The event showcased the company's progress in building a fully integrated and independently operated mRNA platform and highlighted significant breakthroughs across several pipeline programs in cancer and autoimmune diseases. more info >> |
|
| Thursday, June 12, 2025 |
|
|
NEFECON(R) and EVER001 Drive Synergistic Progress as Everest Medicines Advances |
| At the 62nd Congress of the European Renal Association (ERA 2025), Everest Medicines presented new results findings on both NEFECON(budesonide delayed release capsules), the world's first and only approved therapy that directly targets the underlying cause of IgA nephropathy (IgAN), and EVER001, a next-generation covalent reversible BTK inhibitor. more info >> |
|
| Monday, June 9, 2025 |
|
|
Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025 |
| At the 62nd European Renal Association Congress (ERA 2025), Everest Medicines unveiled new clinical data on EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor, in patients with primary membranous nephropathy (pMN). more info >> |
|
| Wednesday, May 7, 2025 |
|
|
Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China |
| Everest Medicines (HKEX: 1952.HK) today announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National Medical Products Administration (NMPA). more info >> |
|
| Tuesday, April 22, 2025 |
|
|
Everest Medicines Announces Approval of 'B' Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong Limited (the 'Stock Exchange') has approved the Company's application to remove the "B" marker from its stock short name, as the company has satisfied the requirements of the listing rules at the Stock Exchange. more info >> |
|
| Friday, March 7, 2025 |
|
|
Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation |
| Everest Medicines' stock (1952.HK) surged today, opening higher and maintaining strong momentum throughout the trading day. By market close, the stock had risen 20.12% to HK$60.6, bringing the company's total market capitalization to HK$19.791 billion. more info >> |
|
| Wednesday, February 19, 2025 |
|
|
Goldman Sachs Raises Everest Medicines' Target Price to HK$48.32 on Stronger Commercial and R&D Outlook |
| Goldman Sachs' latest report on China's biotechnology sector highlights Everest Medicines (1952.HK) as a company on track to achieve EBITDA break-even by the end of 2025. This outlook is driven by the accelerated commercialization of Nefecon(R), which was recently included in China's National Reimbursement Drug List (NRDL). more info >> |
|
| Thursday, January 2, 2025 |
|
|
Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy |
| Everest Medicines (HKEX 1952.HK, Everest , or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that with the official implementation of the latest update of the National Reimbursement Drug List ('NRDL') on January 1, 2025, NEFECON will apply the NRDL pricing, which will benefit more IgA nephropathy (IgAN) patients. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
A New Benchmark for Specialized Technology Stocks in Hong Kong! CiDi's Listing Marks a New Chapter in Commercial Intelligent Driving
Dec 19, 2025 10:30 HKT/SGT
|
|
|
Air T, Inc. Announces Closing of Regional Express Acquisition
Dec 19, 2025 06:10 HKT/SGT
|
|
|
MHI Participates in Demonstration Testing of Vehicle-Infrastructure Integration System for Autonomous Buses in Shimotsuke City
Dec 19, 2025 3:24 JST
|
|
|
NEC and emaratech Collaborate on Biometric Smart Gates Supporting UAE Airport Operations
Dec 19, 2025 3:06 JST
|
|
|
Fujitsu to showcase mobility and physical AI tech at CES 2026
Dec 19, 2025 2:42 JST
|
|
|
Kirin and Fujitsu elucidate a novel gut-brain axis mechanism of citicoline for the first time worldwide through AI-based analysis and experimental validation leveraging drug discovery DX technology
Dec 19, 2025 2:06 JST
|
|
|
TANAKA PRECIOUS METAL GROUP and TANAKA MIRAI Lab. Released Their Fourth Collaborative Musical Work with Sound Wellness Lab (Della): "Precious Metal Orchestra - A Musical Voyage through the Sound of Precious Metals for Christmas" now available for streaming. 
Dec 18, 2025 22:00 JST
|
|
|
Focus Graphite Announces Final Results From 2022 Drill Program at Lac Tetepisca; West Limb Extends Mineralized Strike to 8 KM
Dec 18, 2025 18:09 HKT/SGT
|
|
|
Spritzer MerryLand Returns This Year-End, Bringing Magical Festive Cheer to Taiping
Dec 18, 2025 17:44 HKT/SGT
|
|
|
PropertyGuru Asia Real Estate Summit spotlights PropertyGuru Week 2025 with conversations on 'Trusted Marketplaces and Thriving Communities'
Dec 18, 2025 09:00 HKT/SGT
|
|
|
TruMerit and NAPNAP Team Up to Develop a Global Micro-credential for Pediatric Nursing Care
Dec 18, 2025 07:00 HKT/SGT
|
|
|
1World Online and Culinary Heritage Announce Strategic Partnership and Joint Launches in Europe
Dec 17, 2025 23:29 HKT/SGT
|
|
|
Anson Resources: Update on Cooperation between Anson and POSCO Holdings for DLE Green River Demonstration Plant
Dec 17, 2025 07:00 HKT/SGT
|
|
|
AWM Wraps Up 2025 with Multiple Surf Venue Grand Openings
Dec 16, 2025 23:05 HKT/SGT
|
|
|
Eastman, AstraZeneca, Kraft Heinz, and P&G Recognized with OMP Supply Chain Awards
Dec 16, 2025 22:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
